1. Epigenetic alterations are common in lung cancers and affect genes like CDKN2A. Methylation of these genes can predict lymph node recurrence in stage I cancers. 2. The p53 tumor suppressor gene is frequently mutated in lung cancers, especially SCLC and squamous cell NSCLC, due to smoking-related DNA damage. Mutations in p53 downstream effectors also contribute to lung cancer pathogenesis. 3. Deregulation of cell cycle, apoptosis, and growth factor signaling pathways involved in lung cancer development and progression include alterations in p16/INK4A, LKB1/AMPK/mTOR, immune checkpoint proteins, telomerase, BCL2, death receptors,